Lumipulse G pTau217/β-Amyloid 1-42—for the diagnosis of Alzheimer’s disease. It demonstrated 91.7% sensitivity and 97.3% ...

The START Center for Cancer Research dosed the first patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent ...

The FDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), the first targeted therapy for previously ...

ONCOLife is delighted to announce that Dr İlkiz Er Dağ, MD, MBA, has joined the company as Project Director for Oncology ...

The V Foundation for Cancer Research, a top-rated cancer charity, announced an exciting partnership with Cancer Vaccine ...

New 10-year results from the APHINITY trial show that adding pertuzumab (Perjeta®) to trastuzumab (Herceptin®) and ...

CytomX's CX-2051, a PROBODY® EpCAM-targeted antibody-drug conjugate (ADC), showed a 28% confirmed response rate and 5.8-month ...

Leucid Bio has dosed the first patient in its Phase 1 AERIAL trial of LEU011, an NKG2D-targeting CAR-T therapy for solid ...

The Multidisciplinary Maze Oncology care today involves a constellation of specialists. According to the survey, cancer patients typically interact with at least five different providers throughout ...

Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly improved disease-free survival in high-risk non-muscle-invasive bladder cancer.

The FDA granted accelerated approval to Avutometinib + Defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. In the Phase 2 RAMP 201 trial, the oral combination achieved a 44% overall ...